On July 20, 2026, Law No. 15,471/2026 was enacted, establishing the National Health Strategy for Brazil’s Health Economic-Industrial Complex (Ensceis, in Portuguese). Published in, the Official Gazette (DOU, in Portuguese), on July 21, the law also amends Law No. 6,360/1976, the Administrative Procurement Law (No. 14,133/2021), and the Organic Health Law (No. 8,080/1990). It entered into force on its publication date.

What is the Ensceis 

The Ensceis formalizes Brazil’s industrial policy for the health sector. Its core objectives are to reduce productive and technological dependence on foreign sources, strengthen domestic production of medicines, active pharmaceutical ingredients (APIs), and other strategic products, and ensure sustainable access to health technologies through the Unified Health System. 

The law establishes Strategic Health Companies (EES), Strategic Health Products (PES), and three partnership instruments: Productive Development Partnerships (PDPs), the Local Development and Innovation Program (PDIL), and Health Technology Procurement Orders (Etecs). 

Strategic Health Companies (EES): eligibility and benefits 

An EES is a public or private legal entity accredited by the Executive Branch upon meeting minimum conditions: having productive and R&D activities as its corporate purpose, demonstrating technical, operational, financial, and regulatory capacity, and holding, within Brazil, industrial facilities for PES manufacturing, a track record of productive activity, and the capacity to ensure continuity and expansion. For these companies, the law provides: 

• Regulatory priority in the analysis and processing of regulatory submissions, including marketing authorizations, licenses, and authorizations (Art. 33, I) — a directly relevant provision for companies which have plans for a PES development; 
• Incentives for international market insertion for high-value-added products driven by research, development, and innovation (Art. 3, VIII); 
• Regulatory simplification and integration of production chains and R&D activities (Art. 3, §2); 
• Access to favorable credit lines from BNDES (Art. 34), including competitive rates, flexible repayment terms, and grace periods; 
• Preference margins in public procurement (Art. 27), applicable when EES productive capacity covers at least 30% of the quantity to be acquired. 

Key points for the regulated sector 

The regulatory priority in Art. 33 requires further Executive regulation (publication of corresponding Decree) and ANVISA regulation (specific regulatory instruments) to produce practical effects. There is currently no definition of how EES accreditation will be operationalized with ANVISA, nor which categories of regulatory processes will be prioritized. The Agency stated that the work being carried out by ANVISA is aligned with this new regulatory framework and highlighted that the sectors under its regulation account for 23% of Brazil’s Gross Domestic Product (GDP).

Measures aimed at reducing backlogs, shortening review timelines, and decreasing the regulatory workload were outlined, enabling the completion of applications for 261 synthetic drugs and 46 biological products and radiopharmaceuticals.

Companies interested in these provisions should stay tuned for the publication of the regulatory acts that will put these provisions into practice.